# Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation

> **NCT06832085** · PHASE4 · RECRUITING · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 150 (estimated)

## Conditions studied

- Tobacco

## Interventions

- **DRUG:** Nicotine Replacement Therapy (Nicotine patch plus NRT gum or lozenge)
- **DRUG:** Cytisine
- **DRUG:** Varenicline (Champix)

## Key facts

- **NCT ID:** NCT06832085
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2027-04-30
- **Final completion:** 2027-10-30
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-03-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06832085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06832085, "Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06832085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*